The ReProgram

ReProgram Episode 25: 🩸 YOUR BLOOD MAY BE AGING BEFORE YOU ARE🧠 Episode OverviewBlood aging is often overlooked, but the hematopoietic stem cells inside your bone marrow carry a decades-long history.Your blood is not just a fluid; it is a continuously renewing organ system. As the stem cells that manufacture your blood cells age, they can shift immune composition and increase susceptibility to inflammation. This process is central to understanding how systemic aging actually unfolds, moving beyond simple protein panels or biological clocks to look at the cellular machinery that sustains you.We examine the reality of clonal hematopoiesis, known as CHIP, and why it acts as a risk marker rather than a diagnosis. By separating mechanism from marketing, we clarify what parabiosis experiments and plasma exchange can—and cannot—actually achieve in human biology. Understanding blood aging helps us prioritize evidence-based outcomes over the hype of rejuvenation.Subscribe to The ReProgram for scientist-led longevity biology breakdowns, and let us know in the comments if you want a deeper look at specific plasma-related interventions.#BloodAging #LongevityScience #HealthyAging #TheReProgram🎙️ The ReProgram PerspectiveBlood aging forces us to rethink a familiar assumption. The cells circulating today may be new, but their factory - the hematopoietic stem-cell system and its marrow niche - has been shaped by decades of stress, inflammation, mutation, and repair.The biology is compelling because it connects systems that are often discussed separately: immunity, cancer risk, vascular inflammation, tissue repair, and aging. CHIP is a particularly powerful example. A mutation beginning in one stem cell can eventually influence enormous numbers of immune cells and potentially affect organs far beyond the bone marrow.But risk is not destiny, and mechanism is not treatment. CHIP should not be treated as leukemia, a mouse rejuvenation experiment should not be presented as a human anti-aging therapy, and a change in circulating proteins or an aging clock should not be confused with better function, fewer diseases, or longer life.The standard for a credible rejuvenation intervention should be transparent: disclose the intervention, pre-register the trial, define clinically meaningful outcomes, use appropriate controls, report adverse events, and publish the full results. Longevity science moves forward when fascinating biology is tested with standards strong enough to survive the hype around it.Office Artifact On the desk: GIANT MICROBES Blood Cells⏱️ Chapters00:00 The Blood Factory: Understanding Blood Cell Production01:26 Aging Blood: Impacts on Health and Disease02:38 The Role of Stem Cells in Blood Renewal06:23 Immune Aging: The Complexity of Immune Responses08:07 Clonal Hematopoiesis: A New Layer of Blood Aging10:16 The Link Between Blood Aging and Cardiovascular Disease12:52 Restoring Youth: Potential Strategies for Blood Rejuvenation16:52 Parabiosis: The Young Blood Experiment19:40 Plasma exchange: biology versus hype21:15 Emerging Treatments: The One Generation Approach25:09 Practical Takeaways: Managing Blood Health

Welcome to The ReProgram.Longevity science moves a lot slower than longevity marketing.The ReProgram explores the biology of aging, longevity drugs, regenerative medicine, nutrition, exercise, biotechnology, and the emerging science that may help us live longer, healthier lives.Mechanism over marketing. Evidence over anecdotes. Trade-offs over hype.Understand Aging. Build Resilience. Extend Healthspan.

🎬 EPISODE OVERVIEWEvery cell in your body contains essentially the same DNA, yet a neuron behaves nothing like a skin cell. So what actually gives a cell its identity — and how permanent is that identity?In this episode, Dr. George Murphy sits down with epigenetics and cellular reprogramming expert Dr. Jose Polo to explore how cells establish identity, how that identity can be rewritten, and what reprogramming really means for aging and rejuvenation.They discuss why cellular reprogramming is not the same thing as rejuvenation, Jose’s concept of “cell elasticity,” the danger of pushing a cell so far that it loses its identity, and the possibility of using targeted cell conversion as regenerative medicine.👤 ABOUT THE GUESTDr. Jose M. Polo is Director of the Adelaide Centre for Epigenetics in Australia. His research focuses on the transcriptional and epigenetic mechanisms that govern cell identity, pluripotency, cellular reprogramming, early development, and cancer. His laboratory has helped define the molecular sequence of somatic-cell reprogramming, developed strategies for direct cell-fate conversion, and pioneered human iBlastoid models of early embryonic development.Official profile: https://researchers.adelaide.edu.au/p...🔑 KEYWORDSEpigenetics • Cellular Reprogramming • Cell Identity • Rejuvenation • Partial Reprogramming • Yamanaka Factors • Induced Pluripotent Stem Cells • Cell Elasticity • Epigenetic Clocks • Regenerative Medicine • iBlastoids • Human Embryo Models • Longevity • Aging📌 KEY TAKEAWAYS• Cell identity is regulatory, not genetic. The same genome can produce radically different cell states depending on which programs are active.• Reprogramming is not the same as rejuvenation. Resetting cellular state may erase age-associated features, but that does not automatically mean restored function.• “Cell elasticity” may define the safe window for partial reprogramming. A cell can move away from its identity and return — until it crosses a point where that identity may no longer be recoverable.• Preserving identity is a central safety challenge. A cell that looks younger but loses its specialized function is not a successful rejuvenation strategy.• Cell-fate control could become medicine. Targeted reprogramming may one day convert resident cells into the cell types needed to repair damaged tissues.• iBlastoids demonstrate extraordinary human cell plasticity. But they are experimental models — not embryos — and their biological limits matter.🎙️ THE REPROGRAM PERSPECTIVECellular reprogramming proves that cellular state is not fixed.But making an epigenetic clock move backward is not the same as making a cell healthier.The real goal of rejuvenation should be to restore function and resilience while preserving cell identity, tissue organization, and safety.In longevity science, the most meaningful endpoint is not simply whether a cell looks younger molecularly, but whether it behaves better biologically.⏱️ CHAPTERS02:27 Meet Dr. Jose Polo05:34 What Makes a Cell a Neuron, Skin Cell, or Something Else?08:15 What Is the Epigenome?09:43 Reprogramming Is Not the Same as Rejuvenation11:37 Does Epigenetic Change Cause Aging?13:16 Cell Elasticity: How Far Can Identity Be Pushed?14:39 The Danger Zone: Losing Cell Identity16:48 Reprogramming Cells as Medicine19:20 How Adult Cells Became Human Embryo Models22:21 iBlastoids: What They Are — and What They Are Not23:54 Is Aging a Failure of Cell Identity?25:27 Can We Erase Bad Epigenetic Memory?27:07 What We Still Do Not Understand About Reprogramming📝 NOTES AND REFERENCESLiu X, Tan JP, Schroder J, et al. Modelling human blastocysts by reprogramming fibroblasts into iBlastoids. Nature. 2021;591:627-632.https://doi.org/10.1038/s41586-021-03...*If you value longevity science without the hype, subscribe to The ReProgram.Mechanism over marketing. Evidence over anecdotes. Trade-offs over hype.*

🧠 EPISODE OVERVIEWCreatine is cheap, widely available, and backed by an unusually large body of human research. But its biology extends well beyond the gym.The creatine–phosphocreatine system helps cells rapidly regenerate ATP when energy demand rises—in both muscle and brain.In this episode, we examine the evidence for creatine and muscle preservation, cognition and brain resilience, kidney safety, dosing, and emerging high-dose brain protocols.And most importantly: does any of this make creatine a true longevity supplement?Creatine goes through The ReProgram Scorecard.Mechanism over marketing. Evidence over anecdotes. Trade-offs over hype.🔑 KEYWORDSCreatine • Creatine Monohydrate • Longevity • Healthspan • Muscle • Strength • Resistance Training • Brain Health • Cognition • ATP • Phosphocreatine • Kidney Health • Healthy Aging🧠 KEY TAKEAWAYSEnergy: Creatine helps buffer cellular energy by supporting rapid ATP regeneration.Muscle: The strongest evidence is for strength and performance. Combined with resistance training, creatine can improve strength and augment gains in lean tissue.Brain: Cognitive evidence is promising but less established. Benefits may be most relevant when the brain is under energetic stress.Alzheimer’s: Creatine is not proven to prevent or treat Alzheimer’s disease. Higher-dose brain protocols remain experimental.Kidneys: Safety data in healthy individuals are reassuring. Creatine can raise serum creatinine without necessarily indicating kidney damage.Dose: For most people, 3–5 g/day of creatine monohydrate is the conventional evidence-based approach. Loading is optional.Longevity: Healthspan evidence is not lifespan evidence. There is currently no randomized human evidence that creatine extends human lifespan.🎙️ THE REPROGRAM PERSPECTIVECreatine combines compelling biology, strong human evidence for specific outcomes, low cost, and reassuring safety—without proving that it slows human aging.Sometimes the most interesting intervention is not the newest or most expensive one.📊 THE REPROGRAM SCORECARD: CREATINE⚙️ Mechanistic Plausibility: A💪 Muscle & Performance Evidence: A🧠 Brain & Cognitive Evidence: B🛡️ Safety: A−💰 Cost & Accessibility: A+⏳ Direct Longevity Evidence: C🏆 FINAL REPROGRAM GRADE: A−Verdict: Strong biology, unusually good human evidence for muscle and performance, reassuring safety, low cost, and an increasingly interesting brain story. The longevity claim itself remains unproven.⏱️ CHAPTERS00:00 Creatine: The Longevity Supplement Hiding in Plain Sight?01:58 Understanding Creatine: Mechanisms and Benefits03:56 Scorecard #1: Muscle & Performance07:07 Scorecard #2: The Brain & Cognition09:57 Creatine & Alzheimer’s Disease11:41 Scorecard #3: Safety & the Kidney Question14:39 Other Side Effects15:13 How Much Creatine Should You Take?16:33 What About Higher Doses for the Brain?17:46 The Final ReProgram Scorecard19:06 Final Thoughts: Creatine's Role in LongevityIf you value longevity science without the hype, subscribe to The ReProgram.#Creatine #LongevityScience #HealthyAging #TheReProgram

🐾 EPISODE OVERVIEWThis episode asks a deceptively simple question: Can we actually help our dogs and cats live longer, healthier lives?We explore why companion animals are unusually powerful models of aging, why “one dog year equals seven human years” is biologically wrong, what the Dog Aging Project is revealing, what pet owners can reasonably do today, and where emerging interventions like rapamycin, canine longevity drugs, AIM therapy, and gene therapy fit into the evidence.🔑 KEYWORDSPet longevity, dog aging, cat aging, healthspan, Dog Aging Project, rapamycin, TRIAD Trial, Loyal, feline kidney disease, AIM/CD5L, gene therapy, pet nutrition, body condition, muscle preservation, geroscience, comparative aging, healthy aging, veterinary medicine💡 KEY TAKEAWAYS• Dogs and cats may be powerful real-world models of aging because they share our homes, environments, behaviors, and many naturally occurring diseases.• Dog years are not human years. Aging rates change throughout life and vary dramatically by breed and body size.• For most pets, the strongest longevity strategies today remain surprisingly conventional: appropriate body composition, good nutrition, movement, muscle preservation, dental care, pain management, preventive medicine, and early disease detection.• Rapamycin, dedicated canine longevity drugs, AIM therapy, and gene therapies are scientifically exciting—but they remain at different stages of experimental validation.• Healthspan matters more than lifespan at any cost. More time only matters if we preserve the experiences that make an animal recognizably itself.🎙️ THE REPROGRAM PERSPECTIVEPet longevity is a perfect example of why we need to separate mechanistic plausibility from meaningful outcomes.A supplement that changes a biomarker is not necessarily extending healthspan. An intervention that treats one age-related disease is not necessarily slowing aging throughout the entire organism. And an exciting mouse study is not a reason to start experimenting on your pet.Mechanism over marketing. Evidence over anecdotes. Healthspan over lifespan at any cost.OFFICE ARTIFACTOn the desk: Tut, 3 year old Hairless Peterbald Sphinx: https://www.instagram.com/tutandbeebe.sphynx/⏱️ CHAPTERS0:00 Can Our Pets Live Longer?2:10 Welcome: The Science of Pet Longevity3:52 Why Pets Are Living Aging Studies7:58 The Myth of “Dog Years”10:57 Inside the Dog Aging Project14:19 What Pet Owners Can Do Right Now16:56 Is There a Longevity Diet for Pets?20:08 Oral Health and Preventative Care in Pets21:40 Rapamycin and the TRIAD Trial23:27 The First Canine Longevity Drugs?24:30 AIM Therapy and Feline Kidney Disease27:48 Gene Therapy for Aging-Related Disease29:06 Purina and the Pet Longevity Industry31:02 The ReProgram Pet Longevity Scorecard33:54 Tut, Healthspan & Why More Time Matters